Gold Standard Diagnostics, a Eurofins Technologies Company, Announces a PCR Assay for the Detection of the Monkeypox and Orthopox Virus
23 June 2022 - 5:00PM
Business Wire
Gold Standard Diagnostics Europe continues its response to the
threat of emerging infectious diseases by developing a new
multiplex Real-time PCR assay for the detection of the monkeypox
virus and its differentiation from other orthopox viruses.
The monkeypox virus has raised significant concerns given its
recent spread, with more than 2500 confirmed cases in 37 countries
[1]. These cases are especially unusual as they have not occurred
among travelers returning from the tropical rainforest regions of
Central and West Africa, the common circulation area for the virus.
The Centers for Disease Control and Prevention (CDC) has issued an
alert level 2 for the monkeypox virus.
With the current uncertainty surrounding the clinical
implications of the monkeypox virus, it is crucial to closely
monitor its spread and provide reliable diagnostic solutions for
its identification. This virus belongs to the Orthopoxvirus genus,
which encompasses pathogenic viruses like smallpox (Variola virus;
eradicated), cowpox or buffalopox, which exhibit similar symptoms
in infected patients.
The Mplex Monkeypox, Orthopox Real-time PCR assay uses a
generic target for orthopox viruses and a specific target for
monkeypox and will be available for research use only from the
beginning of July. This product complements Gold Standard
Diagnostics Europe’s suite of assays developed in response to
infectious diseases, such as the GSD NovaPrime and NovaType assay
families, developed for SARS-CoV-2 detection and variant
identification.
Reference [1]
https://www.cdc.gov/poxvirus/monkeypox/response/2022/world-map.html
For more information, please visit Eurofins Technologies
website.
About Eurofins Technologies – a fast growing provider of
diagnostic technologies in the field of immunoassays and molecular
detection methods
Building on the experience and scientific excellence of the
Eurofins Group, Eurofins Technologies is a fast-growing global
provider of diagnostic technologies and industry-leading
ELISA-based instruments in the field of bioanalytical testing for
the food, feed, environmental, animal health, and clinical
diagnostics industries.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With 58,000 staff across a network
of 900 laboratories in 54 countries, Eurofins’ companies offer a
portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220623005096/en/
For further information: Rodrigo Berlie
ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jul 2023 to Jul 2024